Risk factors
Silexion Therapeutics (SLXN) risk factors
Item 1A of every Silexion Therapeutics Corp. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors55 risks3 new1 dropped6 reworded
Silexion focuses heavily on reverse stock splits, Nasdaq listing compliance, and financing dilution risks.
Filed Mar 17, 2026 - FY2024 10-K risk factors53 risks
Silexion is a pre-revenue development-stage biotech company dependent entirely on unproven RNA interference technology for oncology. Operations face extreme regulatory hurdles, intense competition, patent dependencies, and the need for significant capital and personnel.
Filed Mar 18, 2025